Year-over-year earnings per share growth for the last twelve months: apogeetherapeutics.com (APGE)

Symbol and logo of brand Apogee Therapeutics, Inc. (APGE)

The success of Apogee Therapeutics (APGE) is based on the efficacy of APG777 molecules and the speed of FDA approval. Quarterly earnings per share dynamics demonstrate the current trend, where the parameter value reaches -0.60. This confirms the status of an ambitious pioneer in dermatology. The development of rare injections for asthma and dermatitis therapy promises to radically improve patient comfort.

Apogee Therapeutics, Inc. (APGE) - Quarterly EPS earnings growth from 02/21/2024 to 09/19/2026

Analytical breakdowns for Apogee Therapeutics

- share price and expert price forecast:
- company stock exchange capitalization indicators:
Fundamental company analysis:apogeetherapeutics.com - APGE
Manufactured product of Apogee Corp

Apogee Therapeutics (APGE) is developing a portfolio of monoclonal antibodies, mitigating risks through the diversification of therapeutic targets. The efficiency of these R&D investments is reflected in the change in net earnings per share. This metric measures the percentage deviation of the current quarter's EPS from the previous one, revealing the business's scaling rates. Stable growth confirms the issuer's fundamental resilience. By analyzing the quarter-over-quarter EPS dynamics, an investor determines the company's maturity.

Analysis of competing companies

KRYS: Quarterly EPS earnings growth|ARQT - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Vericel|Year-over-year earnings per share growth for the last 12 months ORKA (orukatx.com)|Year-over-year earnings per share growth for the last twelve months Sanara (SMTI)|DBV Technologies - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Solesence SLSN|journeymedicalcorp.com (DERM) - Earnings per share growth in annualized terms for the last twelve months|FBRX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share trend for the last twelve months EMPG|SLGL (sol-gel.com) - Year-over-year net earnings per share growth for the last 12 months|AXIL (AXIL Brands, Inc.) - Year-over-year earnings per share growth for the last twelve months|MDCX (Medicus Pharma Corp) - Quarterly EPS earnings growth|Verrica Pharmaceuticals (VRCA) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months HOTH (Hoth Therapeutics, Inc.)|BFRI - Earnings per share growth in annualized terms for the last twelve months|Quarterly EPS earnings growth VYNE (VYNE Therapeutics)|Year-over-year earnings per one share growth for the last 12 months SNOA|Quoin Pharmaceuticals Ltd. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months Azitra Corporation AZTR|DRMA (Dermata) - Year-over-year net earnings per share growth for the last 12 months|Elevai Labs Inc. (ELAB) - Quarterly EPS earnings growth|RVNC (Revance Therapeutics, Inc.) - Quarterly EPS earnings growth